Market revenue in 2018 | USD 2,325.4 million |
Market revenue in 2027 | USD 4,817.5 million |
Growth rate | 8.4% (CAGR from 2018 to 2027) |
Largest segment | Hormonal therapy |
Fastest growing segment | Immunotherapy |
Historical data covered | 2016 - 2017 |
Base year for estimation | 2018 |
Forecast period covered | 2019 - 2027 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy |
Key market players worldwide | Sanofi SA, Johnson & Johnson, Pfizer Inc, Astellas Pharma Inc, Bayer AG |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to castrate-resistant prostate cancer market will help companies and investors design strategic landscapes.
Hormonal therapy was the largest segment with a revenue share of 82.8% in 2018. Horizon Databook has segmented the Europe castrate-resistant prostate cancer market based on chemotherapy, hormonal therapy, immunotherapy, radiotherapy covering the revenue growth of each sub-segment from 2016 to 2027.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe castrate-resistant prostate cancer market, including forecasts for subscribers. This continent databook contains high-level insights into Europe castrate-resistant prostate cancer market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account